Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease

Summary by pharmatimes.com
Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.Cross Cancel Icon

1 Articles

pharmatimes.compharmatimes.com

Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease

Early trial shows more than 50% LRRK2 reduction and supports expansion into other neurodegenerative conditions

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

pharmatimes.com broke the news in on Thursday, March 19, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Parkinson's Disease icon

Parkinson's Disease

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal